Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Date:11/11/2008

ent ratio of 6.4 to 1 and $12.4 million in cash and cash equivalents on September 30, 2008. The Company had Stockholders' Equity of $35.1 million, with total assets of $38.5 million versus total liabilities of $3.4 million. For the first three months of fiscal year 2009, the Company generated $0.5 million in cash from operations versus $1 million for the same period in 2008.

Business Development

Tianyin has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Laonian Kechuan Tablets in the dosage form of 0.25 gram/tablet (SFDA approval number Z20083360) and Fuke Zhidai Tablets in the dosage form of 0.4 gram/tablet (SFDA approval number Z20083375). Laonian Kechuan Tablets is a TCM drug that effectively treats asthma in people aged 60 or above. Fuke Zhidai Tablets is a TCM drug used to treat abnormal leucorrhea, which is caused by chronic cervicitis, endometritis and endocolpitis. The Company plans to launch Laonian Kechuan Tablets and Fuke Zhidai Tablets in the domestic market and begin recording revenue in November 2008 and December 2008, respectively. The Company launched the production of Azithromycin Dispersible Tablets in August 2008 and is due to market the new product in October 2008. Azithromycin is highly effective in treating upper and lower respiratory tract infections and other bacterial infections in the skin and reproductive system. Tianyin received approval from the Chinese State Food and Drug Administration (SFDA) to produce Azithromycin Dispersible Tablets in December 28, 2007.

Tianyin continues to invest in information systems and post-marketing studies and monitoring to improve efficiency. The Company is also making progress constructing the plant they started building in the end of April 2008. Also, Tianyin continues to evaluate acquisition opportunities which will complement the existing product and manufacturing lines, as well as provide accretive earnings growth.

Tianyin's common st
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
4. Tianyin Pharmaceutical Appoints Three New Independent Board Members
5. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
6. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
7. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
8. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
9. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
10. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
11. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Proove Biosciences , ... industry leading research and data on the association between ... American Academy of Pain Management’ s 25th ... Arizona at the , Proove Biosciences ... and genetic predisposition to opioid misuse risk in chronic ...
(Date:9/23/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, ... consultants to its team for further development of ... proprietary cell permeable peptide platform technology derived from ... the eye. Ms. Holly ...
(Date:9/23/2014)... Austin, TX (PRWEB) September 23, 2014 ... newest fertility clinic in South Austin, expanding a Central ... Austin and San Antonio. The satellite office for the ... and andrology options to the South Austin, Buda, Kyle ... bring effective and affordable fertility treatment directly to individuals ...
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... Zemea® propanediol, has been independently evaluated by NSF International and now ... Protection Agency (EPA) Design for the Environment (DfE) screen. Zemea® ... Products joint venture. , ... Loudon, TN (Vocus) December ...
... MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM ... an oncology company that identifies, develops and ... announced that it has received clearance from ... II, double-blind, randomized trials for nimotuzumab, its ...
... Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced today ... update on the progress of Sangamo,s ZFP Therapeutic,development programs ... pm (PT) on Monday, January 12, 2009 at the ... The presentation will be webcast live and ...
Cached Biology Technology:Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria 2Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference 2
(Date:9/23/2014)... Ill. Scientists have scoured cow rumens and termite ... cell walls for the production of next-generation biofuels, but ... in the human lower intestine, researchers report. , Their ... the National Academy of Sciences , is the first ... microbes in the human gut can digest fiber, breaking ...
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... SPRINGS, Florida , September 23, 2014 ... for innovative companies in tech sector position for significant investor ... products & services.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Mobileye N.V. (NYSE: MBLY ... Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7
... requires the same protein molecule that neurons need to ... to new research from the University of Illinois at ... the online journal PLOS ONE . , The ... cells into neurons and the process whereby cancer cells ...
... -- Critical to the recovery efforts following the devastating effects ... ability to assess damage within the reactor,s core. A study ... of scientists from Los Alamos National Laboratory (LANL) shows that ... to the reactor cores and locating the melted fuel. ...
... beverages containing toxins believed to pose potential risks to developing ... in Riverside and San Diego, suggesting that health care providers ... of hidden toxins in the food supply. In a ... Journal "Consumption habits of pregnant women and implications ...
Cached Biology News:Protein involved in nerve-cell migration implicated in spread of brain cancer 2Getting to the core of Fukushima 2Diets of pregnant women contain harmful, hidden toxins 2Diets of pregnant women contain harmful, hidden toxins 3Diets of pregnant women contain harmful, hidden toxins 4
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: